EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Accurate Detection of α‐Synuclein Seeds in Cerebrospinal Fluid from Isolated Rapid Eye Movement Sleep Behavior Disorder and Patients with Parkinson's Disease in the DeNovo Parkinson (DeNoPa) Cohort

Luis Concha-Marambio, Sandrina Weber iD, Carly M Farris, Mohammed Dakna, Elisabeth Lang, Tamara Wicke, Yihua Ma, Maritta Starke, Jens Ebentheuer, Friederike Sixel-Döring, Maria-Lucia Muntean, Sebastian Schade iD und 3 weitere

Movement Disorders · 2023-04 · 38 (4) · 567-578

DOI: 10.1002/mds.29329 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Movement Disorders, online erschienen am 13.02.2023. Verfasst von Luis Concha-Marambio und 14 weiteren Autor:innen. Beteiligte Einrichtung: Research and Development Unit, Amprion Inc., San Diego, California, USA. Hauptthemen laut MEDLINE: alpha-Synuclein, Parkinson Disease, REM Sleep Behavior Disorder. Die Arbeit wurde bisher 125-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIH HHS, NIA NIH HHS, Foundation for the National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Misfolded α‐synuclein (αSyn) aggregates (αSyn‐seeds) in cerebrospinal fluid (CSF) are biomarkers for synucleinopathies such as Parkinson's disease (PD). αSyn‐seeds have been detected in prodromal cases with isolated rapid eye movement sleep behavior disorder (iRBD).

Objectives

The objective of this study was to determine the accuracy of the αSyn–seed amplification assay (αS‐SAA) in a comprehensively characterized cohort with a high proportion of PD and iRBD CSF samples collected at baseline.

Methods

We used a high‐throughput αS‐SAA to analyze 233 blinded CSF samples from 206 participants of the DeNovo Parkinson Cohort (DeNoPa) (113 de novo PD, 64 healthy controls, 29 iRBD confirmed by video polysomnography). Results were compared with the final diagnosis, which was determined after up to 10 years of longitudinal clinical evaluations, including dopamine‐transporter–single‐photon emission computed tomography (DAT‐SPECT) at baseline, CSF proteins, Movement Disorder Society–Unified Parkinson's Disease Rating Scale, and various cognitive and nonmotor scales. Results αS‐SAA detected αSyn‐seeds in baseline PD‐CSF with 98% accuracy. αSyn‐seeds were detected in 93% of the iRBD cases. αS‐SAA results showed higher agreement with the final than the initial diagnosis, as 14 patients were rediagnosed as non‐αSyn aggregation disorder. For synucleinopathies, αS‐SAA showed higher concordance with the final diagnosis than DAT‐SPECT. Statistically significant correlations were found between assay parameters and disease progression.

Conclusions

Our results confirm αS‐SAA accuracy at the first clinical evaluation when a definite diagnosis is most consequential. αS‐SAA conditions reported here are highly sensitive, enabling the detection of αSyn‐seeds in CSF from iRBD just months after the first symptoms, suggesting that αSyn‐seeds are present in the very early prodromal phase of synucleinopathies. Therefore, αSyn‐seeds are clear risk markers for synuclein‐related disorders, but not for time of phenoconversion. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

alpha-SynucleinParkinson DiseaseREM Sleep Behavior DisorderHumansSynucleinopathies

Stichwörter der Autor:innen

CSFRBDearly Parkinson's diseaseseed amplification assayα-Synuclein

Substanzen

alpha-Synuclein

Autor:innen und Institutionen

  • Research and Development Unit, Amprion Inc., San Diego, California, USA.
  • Department of Neurology, University Medical Centre Goettingen, Goettingen, Germany.
  • Paracelsus-Elena-Klinik, Kassel, Germany.
  • Department of Neurology, Philipps University Marburg, Marburg, Germany.
  • Department of Neurosurgery, University Medical Centre Goettingen, Goettingen, Germany.
  • Mitchell Center for Alzheimer's Disease and Related Brain Disorders, University of Texas McGovern Medical School, Houston, Texas, USA.

ORCID-Profile: Sandrina Weber, Sebastian Schade, Brit Mollenhauer

Förderung

  • NIH HHS
  • NIA NIH HHS
  • Foundation for the National Institutes of Health
  • Michael J. Fox Foundation

Zitieren

APA

Concha-Marambio, L., Weber, S., Farris, C. M., Dakna, M., Lang, E., Wicke, T., Ma, Y., Starke, M., Ebentheuer, J., Sixel-Döring, F., Muntean, M. L., Schade, S., Trenkwalder, C., Soto, C., & Mollenhauer, B. (2023). Accurate Detection of α‐Synuclein Seeds in Cerebrospinal Fluid from Isolated Rapid Eye Movement Sleep Behavior Disorder and Patients with Parkinson's Disease in the DeNovo Parkinson (DeNoPa) Cohort. Movement Disorders, 38(4), 567-578. https://doi.org/10.1002/mds.29329

Vancouver

Concha-Marambio L, Weber S, Farris CM, Dakna M, Lang E, Wicke T, et al. Accurate Detection of α‐Synuclein Seeds in Cerebrospinal Fluid from Isolated Rapid Eye Movement Sleep Behavior Disorder and Patients with Parkinson's Disease in the DeNovo Parkinson (DeNoPa) Cohort. Movement Disorders. 2023;38(4):567-578. doi:10.1002/mds.29329

BibTeX
@article{ConchaMarambio2023,
  author = {Concha-Marambio, Luis and Weber, Sandrina and Farris, Carly M and Dakna, Mohammed and Lang, Elisabeth and Wicke, Tamara and Ma, Yihua and Starke, Maritta and Ebentheuer, Jens and Sixel-Döring, Friederike and Muntean, Maria-Lucia and Schade, Sebastian and Trenkwalder, Claudia and Soto, Claudio and Mollenhauer, Brit},
  title = {Accurate Detection of α‐Synuclein Seeds in Cerebrospinal Fluid from Isolated Rapid Eye Movement Sleep Behavior Disorder and Patients with Parkinson's Disease in the DeNovo Parkinson (DeNoPa) Cohort},
  journal = {Movement Disorders},
  year = {2023},
  volume = {38},
  number = {4},
  pages = {567--578},
  doi = {10.1002/mds.29329}
}
Kostenlos starten →